TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37753555

Group type: EXPERIMENTAL
Intervention: Brief-motivational interviewing (MI)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Traditional oral hygiene instructions (OHI)
Number of subjects: 58
Study: 34758629

Group type: EXPERIMENTAL
Intervention: Well-Formulated Ketogenic Diet (WFKD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Whole-Food Diet (WFD)
Number of subjects: 24
Study: 34651102

Group type: EXPERIMENTAL
Intervention: E-SBIRT intervention and pamphlet
Number of subjects: 240

Group type: COMPARATOR
Intervention: Pamphlet of drug abuse prevention
Number of subjects: 240
Study: 35703895

Group type: EXPERIMENTAL
Intervention: BreatheWell Wear and conventional care
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 30
Study: 34181182

Group type: EXPERIMENTAL
Intervention: Artificial intelligence model
Number of subjects: 301

Group type: COMPARATOR
Intervention: Maximum standardized uptake value
Number of subjects: 301
Study: 32363613

Group type: EXPERIMENTAL
Intervention: RHT3201 (1.0 × 10^10 CPU/d)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: RHT3201
Number of subjects: 66

Group type: COMPARATOR
Intervention: RHT3201 and Placebo
Number of subjects: 66
Study: 36028775

Group type: EXPERIMENTAL
Intervention: Individual nutrition therapy (five in-person visits and three phone calls) and freely delivered energy- and protein-rich foods
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 106
Study: 33636344

Group type: EXPERIMENTAL
Intervention: Behavioral intervention including nudges within the electronic health record (EHR) such as accountable justification, precommitment to address high-risk prescriptions, and PainTracker.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving no EHR-based intervention.
Number of subjects: 0
Study: 32561245

Group type: EXPERIMENTAL
Intervention: AD/IMH/PAU patients
Number of subjects: 133

Group type: COMPARATOR
Intervention: Population referents
Number of subjects: 133
Study: 36104145

Group type: EXPERIMENTAL
Intervention: Supported Prep-to-Play intervention (with physiotherapist support)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Unsupported phase (usual routines, no face-to-face support)
Number of subjects: 140
Study: 33407797

Group type: EXPERIMENTAL
Intervention: Shared follow-up care intervention (GOSPEL I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual specialist‐led follow-up care
Number of subjects: 60
Study: 33184653

Group type: EXPERIMENTAL
Intervention: Gestational phosphatidylcholine supplementation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 32154888

Group type: EXPERIMENTAL
Intervention: Written resources
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Written resources plus in-person assistance
Number of subjects: 611
Study: 35468299

Group type: EXPERIMENTAL
Intervention: Thulium laser (multiple shots) in group A
Number of subjects: 148

Group type: COMPARATOR
Intervention: Thulium laser (one shot with a manual perforator) in group B
Number of subjects: 148
Study: 33212438

Group type: EXPERIMENTAL
Intervention: IG2: motivation‐based intervention with end‐of‐life perspective
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: IG3: combination of IG1 and IG2
Number of subjects: 168

Group type: COMPARATOR
Intervention: CG: control group
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: IG1: value‐based intervention with end‐of‐life perspective
Number of subjects: 168
Study: 33175238

Group type: EXPERIMENTAL
Intervention: Counseling based on the PLISSIT model (4 sessions, 45-75 min each)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 62
Study: 32798761

Group type: EXPERIMENTAL
Intervention: Layer‐by‐layer wound irrigation with gentamicin‐saline solution
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Wound irrigation with saline solution
Number of subjects: 205

Group type: COMPARATOR
Intervention: No irrigation (Control group)
Number of subjects: 205
Study: 32034857

Group type: EXPERIMENTAL
Intervention: Remote ischemic per-postconditioning (RIperpostC)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 115
Study: 32599066

Group type: EXPERIMENTAL
Intervention: Invasive mediastinal staging
Number of subjects: 332
Study: 33729499

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Two-step Mendelian randomization (MR) analyses
Number of subjects: 280

Group type: COMPARATOR
Intervention: DNA methylation
Number of subjects: 280
Study: 36179657

Group type: EXPERIMENTAL
Intervention: Cascading deep supervision U-Net (CSNet) model
Number of subjects: 162

Group type: COMPARATOR
Intervention: Traditional U-Net model
Number of subjects: 162

Group type: COMPARATOR
Intervention: Supervision U-Net (SNet) model
Number of subjects: 162
Study: 33892287

Group type: EXPERIMENTAL
Intervention: Aberrant Behavior Checklist (ABC)
Number of subjects: 122
Study: 34524103

Group type: EXPERIMENTAL
Intervention: IMPACT intervention (app-based program)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Enhanced web-based resources (control)
Number of subjects: 80
Study: 32359506

Group type: EXPERIMENTAL
Intervention: Autologous HSCT
Number of subjects: 1503

Group type: COMPARATOR
Intervention: Bortezomib-melphalan-prednisone (VMP)
Number of subjects: 1503

Group type: EXPERIMENTAL
Intervention: Bortezomib-lenalidomide-dexamethasone (VRD) consolidation therapy
Number of subjects: 1503

Group type: COMPARATOR
Intervention: No consolidation
Number of subjects: 1503

Group type: COMPARATOR
Intervention: VMP
Number of subjects: 1503
Study: 35463507

Group type: EXPERIMENTAL
Intervention: Verbal and non-verbal de-escalation training for staff teams on experimental wards
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no de-escalation training)
Number of subjects: 0
Study: 32495862

Group type: EXPERIMENTAL
Intervention: Overexpression of miR‐18a in OC cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restoration of miR‐18a
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low miR‐18a expression
Number of subjects: 0
Study: 34527078

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 16
Study: 32513507

Group type: EXPERIMENTAL
Intervention: Pharmacist- and nurse-driven metabolic monitoring protocol
Number of subjects: 160
Study: 36257695

Group type: EXPERIMENTAL
Intervention: Practice support curriculum delivered by trained practice coaches, including a kickoff meeting, 3 months of intensive support, 9 months of ongoing support, and access to online learning materials and expert faculty.
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Practice support curriculum delivered by trained practice coaches.
Number of subjects: 264
Study: 33263418

Group type: EXPERIMENTAL
Intervention: Margetuximab plus retifanlimab with/without chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Margetuximab plus tebotelimab with chemotherapy
Number of subjects: 0
Study: 32521394

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study: 35972164

Group type: EXPERIMENTAL
Intervention: Slow music (study arm B)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Fast music (study arm C)
Number of subjects: 600

Group type: COMPARATOR
Intervention: No music (study arm A)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: All study arms
Number of subjects: 600
Study: 34341242

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chemomechanical removal (Papaya® gel)
Number of subjects: 40
Study: 32372118

Group type: EXPERIMENTAL
Intervention: Intravenous TXA (15 mg/kg)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Intra-articular TXA (2 g)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Patients > 65 years
Number of subjects: 195
Study: 32488361

Group type: EXPERIMENTAL
Intervention: Split-leg modified lateral position (SL-MLP)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard prone position (PP)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study: 34030169

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg daily, up-titrated after 25 mg daily for 1 week)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 35781129

Group type: EXPERIMENTAL
Intervention: Single, high‐dose intravenous iron therapy (20 mg/kg ferric derisomaltose)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Oral iron supplementation (100 mg ferrous sulphate orally twice daily)
Number of subjects: 110
Study: 34354033

Group type: EXPERIMENTAL
Intervention: Accountable Care Team (ACT) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (units not implementing ACT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT intervention
Number of subjects: 0
Study: 36355805

Group type: EXPERIMENTAL
Intervention: Crizanlizumab 5.0 mg/kg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Crizanlizumab 7.5 mg/kg
Number of subjects: 57
Study: 34684650

Group type: EXPERIMENTAL
Intervention: Water supplementation group (1000 mL purified water)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Water supplementation group (500 mL purified water)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Water supplementation group (200 mL purified water)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No water supplementation group (NW group)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Dehydration test
Number of subjects: 76
Study: 32749468

Group type: EXPERIMENTAL
Intervention: Emotional Memory Reactivation (EMR‐ECT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control Memory Reactivation (CMR‐ECT)
Number of subjects: 66
Study: 33583493

Group type: EXPERIMENTAL
Intervention: AASM criteria
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Randerath algorithm
Number of subjects: 50
Study: 35685548

Group type: EXPERIMENTAL
Intervention: Radiomics model based on enhanced T1WI
Number of subjects: 114
Study: 34618889

Group type: EXPERIMENTAL
Intervention: Preoperative paravertebral block with 0.35 ml/kg 0.75% ropivacaine
Number of subjects: 380

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 380
Study: 32086874

Group type: EXPERIMENTAL
Intervention: Ethmoidal drug-eluting stent (DES) with triamcinolone acetonide stents (n = 34)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Topical intranasal corticosteroid (triamcinolone acetonide nasal spray) (n = 29)
Number of subjects: 63
Study: 34669935

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Healthy Eating (HE) intervention
Number of subjects: 436

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 436
Study: 32133871

Group type: EXPERIMENTAL
Intervention: Tailored physical activity intervention
Number of subjects: 822

Group type: COMPARATOR
Intervention: Control group (norm-active participants)
Number of subjects: 822
Study: 34735183

Group type: EXPERIMENTAL
Intervention: eBook with a character who modeled dialogic questioning (experimental)
Number of subjects: 73

Group type: COMPARATOR
Intervention: eBook without modeling (control)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Choice condition (choose between versions)
Number of subjects: 73
Study: 34226654

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH, Genotonorm 0.4 mg, Pfizer Pharmaceuticals) administered subcutaneously daily for one year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered subcutaneously daily for one year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive and long-lasting rehabilitation program
Number of subjects: 0
Study: 32925060

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20
Study: 35222690

Group type: EXPERIMENTAL
Intervention: 3D-slicer software-assisted endoscopic treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional imaging positioning craniotomy (Control)
Number of subjects: 120
Study: 35469232

Group type: EXPERIMENTAL
Intervention: long‐handled Kaiselu +1 cathartic intervention (Group A)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: long‐handled Kaiselu +2 cathartic intervention (Group B)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: enema plus one cathartic intervention (Group C)
Number of subjects: 61
Study: 34693691

Group type: EXPERIMENTAL
Intervention: Mexidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emoxypine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32618242

Group type: EXPERIMENTAL
Intervention: Mass Drug Administration (MDA)
Number of subjects: 1880

Group type: EXPERIMENTAL
Intervention: Focal Mass Drug Administration (fMDA)
Number of subjects: 1880

Group type: COMPARATOR
Intervention: Standard of Care (Control)
Number of subjects: 1880

Group type: EXPERIMENTAL
Intervention: MDA and fMDA
Number of subjects: 1880

Group type: EXPERIMENTAL
Intervention: Community-wide sensitization program
Number of subjects: 1880
Study: 35833091

Group type: COMPARATOR
Intervention: Fascia Iliaca Block (FIB)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Transmuscular Quadratus Lumborum Block (TQLB)
Number of subjects: 50
Study: 32405121

Group type: EXPERIMENTAL
Intervention: Moral reasoning exercise prior to choice task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no moral reasoning exercise)
Number of subjects: 0
Study: 32951293

Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel
Number of subjects: 529

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 529
Study: 32102782

Group type: EXPERIMENTAL
Intervention: Intervention practices with electronic algorithm, staff educational training, and patient awareness materials.
Number of subjects: 24473

Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 24473

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 24473
Study: 34331505

Group type: EXPERIMENTAL
Intervention: PRESERFLO™ MicroShunt
Number of subjects: 52

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 52
Study: 34037760

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir (SOF/VEL) plus national standard of care
Number of subjects: 80

Group type: COMPARATOR
Intervention: National standard of care alone
Number of subjects: 80
Study: 34918971

Group type: EXPERIMENTAL
Intervention: Very-Low-Carbohydrate Ketogenic Diet (VLCKD) for 140 days
Number of subjects: 0
Study: 32424833

Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment and Hall crown approaches (ARTs)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Dental general anaesthesia (DGA)
Number of subjects: 65
Study: 35599912

Group type: EXPERIMENTAL
Intervention: Pre-sleep protein (PRO) supplement containing 40 g of casein protein (n=10)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-caloric, flavor matched placebo (PLA) (n=8)
Number of subjects: 18
Study: 33772220

Group type: EXPERIMENTAL
Intervention: NBS plus exome sequencing (ES)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Conventional NBS
Number of subjects: 159
Study: 32441675

Group type: EXPERIMENTAL
Intervention: Nurse-provided education about chemotherapy-associated taste disorders
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 53
Study: 35251294

Group type: EXPERIMENTAL
Intervention: Anlotinib in combination with other drugs
Number of subjects: 43

Group type: COMPARATOR
Intervention: Anlotinib monotherapy
Number of subjects: 43
Study: 33146693

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 300
Study: 35662322

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Noradrenaline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 12
Study: 34154552

Group type: EXPERIMENTAL
Intervention: Asdzáán Be'eena' program (11-session intervention)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Mailed non‐monetary incentives (control arm)
Number of subjects: 410
Study: 34487909

Group type: EXPERIMENTAL
Intervention: Rotator Cuff Tear Group (RCT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both GTA and CSA values
Number of subjects: 49
Study: 34261764

Group type: EXPERIMENTAL
Intervention: Abstract with spin
Number of subjects: 128

Group type: COMPARATOR
Intervention: Abstract without spin
Number of subjects: 128
Study: 33009865

Group type: EXPERIMENTAL
Intervention: Correlation technique for designing definitive crowns
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Library technique for designing definitive crowns
Number of subjects: 24

Group type: COMPARATOR
Intervention: Interim crowns
Number of subjects: 24
Study: 33067215

Group type: EXPERIMENTAL
Intervention: Chimeric assembly A1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chimeric assembly B1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonchimeric assembly C1
Number of subjects: 20
Study: 35901983

Group type: COMPARATOR
Intervention: Placebo delivery (0 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Steady-state delivery (2 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Random nicotine delivery (RND) (0 mg or 4 mg)
Number of subjects: 45
Study: 34145680

Group type: EXPERIMENTAL
Intervention: Eligible for any study (415 patients, 31.8%)
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: IABP-SHOCK II trial eligibility (26.9%)
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: CS caused by acute myocardial infarction (AMI)
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: Overall trials
Number of subjects: 1305
Study: 32211998

Group type: EXPERIMENTAL
Intervention: Exercise (progressive upright aerobic and resistance exercises targeting the trunk and major muscle groups)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (motor control training and manual therapy)
Number of subjects: 40
Study: 34297099

Group type: EXPERIMENTAL
Intervention: Ultra-proactive TDM algorithm incorporating POCT
Number of subjects: 187

Group type: COMPARATOR
Intervention: Reactive TDM
Number of subjects: 187
Study: 34157312

Group type: EXPERIMENTAL
Intervention: 5 µg/d Cu-IUS
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 20 µg/d Cu-IUS
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 40 µg/d Cu-IUS
Number of subjects: 29
Study: 34864911

Group type: EXPERIMENTAL
Intervention: UPA 15 mg QD monotherapy
Number of subjects: 1916

Group type: EXPERIMENTAL
Intervention: UPA 30 mg QD monotherapy
Number of subjects: 1916

Group type: EXPERIMENTAL
Intervention: UPA 15 mg QD combination therapy
Number of subjects: 1916

Group type: EXPERIMENTAL
Intervention: UPA 30 mg QD combination therapy
Number of subjects: 1916

Group type: COMPARATOR
Intervention: UPA monotherapy
Number of subjects: 1916

Group type: COMPARATOR
Intervention: UPA combination therapy
Number of subjects: 1916
Study: 33607215

Group type: EXPERIMENTAL
Intervention: GB21 acupressure
Number of subjects: 174

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study: 35978405

Group type: EXPERIMENTAL
Intervention: 20-minute motor coordination intervention
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sedentary control condition
Number of subjects: 103
Study: 35278356

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by chemotherapy plus durvalumab and tremelimumab
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus durvalumab
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus durvalumab and tremelimumab
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 124
Study: 35639376

Group type: EXPERIMENTAL
Intervention: Gait plus HVLT‐R decline
Number of subjects: 16855

Group type: EXPERIMENTAL
Intervention: Gait plus 3MS decline
Number of subjects: 16855

Group type: EXPERIMENTAL
Intervention: Gait plus COWAT‐F decline
Number of subjects: 16855

Group type: EXPERIMENTAL
Intervention: Gait plus SDMT decline
Number of subjects: 16855

Group type: EXPERIMENTAL
Intervention: Dual decliners (gait and cognitive decline)
Number of subjects: 16855
Study: 33271042

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Computerized Attention Training (CT)
Number of subjects: 86
Study: 36321352

Group type: EXPERIMENTAL
Intervention: Potassium chloride (KCl) sustained-release tablets, oral dose of 6 g under fasting conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potassium chloride (KCl) sustained-release tablets, oral dose of 6 g under different dietary arrangements
Number of subjects: 0
Study: 33632127

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - Supine position for 2 hours, then semi-seated position with bed angle increased to 45° over 4 hours.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control Group (CG) - Remained in supine position for 6 hours.
Number of subjects: 72
Study: 33422013

Group type: EXPERIMENTAL
Intervention: Integrated care model for chronic condition management (social, behavioral, cognitive interventions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General intervention (control arm)
Number of subjects: 0
Study: 34274940

Group type: EXPERIMENTAL
Intervention: Bendamustine plus rituximab (BR)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 537
Study: 32383050

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg per day)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Gabapentin (100 mg per day)
Number of subjects: 77
Study: 33919513

Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: Plasma folate
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: Vitamin B12
Number of subjects: 2201